Laricchia Alessandra, Khokhar Arif A, Giannini Francesco
Interventional Cardiology Unit, GVM Care & Research Maria Cecilia Hospital, Cotignola, Italy.
Front Cardiovasc Med. 2020 Dec 21;7:583307. doi: 10.3389/fcvm.2020.583307. eCollection 2020.
The tricuspid valve has been neglected for a long time and severe tricuspid regurgitation (TR) was largely undertreated in the past due to a high operative risk. In the last years we observed the development of different less invasive percutaneous options to treat TR. Currently, percutaneous treatments are reserved for high-risk patients presenting with advanced stage disease by which time they are likely to derive a partial benefit at best. There is a limited evidence base, including no randomized trials, to guide the management strategy for severe TR. In the interim we feel that choosing the best device for the most appropriate clinical candidate and with an adequate timing (most probably an "earlier" timing) will be the key combination to improve early and late outcomes of percutaneous treatments.
三尖瓣长期以来一直被忽视，过去由于手术风险高，严重三尖瓣反流（TR）在很大程度上未得到充分治疗。在过去几年中，我们观察到了不同的微创经皮治疗TR的方法的发展。目前，经皮治疗仅适用于患有晚期疾病的高危患者，而到那时他们最多只能获得部分益处。目前指导严重TR管理策略的证据基础有限，包括没有随机试验。在此期间，我们认为为最合适的临床候选者选择最佳装置并在适当的时机（很可能是“更早”的时机）进行治疗，将是改善经皮治疗早期和晚期结果的关键组合。
